1
|
Self-assembled nanomaterials as vaccines for COVID-19 and future pandemics. Nanomedicine (Lond) 2023. [DOI: 10.1016/b978-0-12-818627-5.00006-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023] Open
|
2
|
Cieślińska A, Fiedorowicz E, Rozmus D, Sienkiewicz-Szłapka E, Jarmołowska B, Kamiński S. Does a Little Difference Make a Big Difference? Bovine β-Casein A1 and A2 Variants and Human Health-An Update. Int J Mol Sci 2022; 23:15637. [PMID: 36555278 PMCID: PMC9779325 DOI: 10.3390/ijms232415637] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2022] [Revised: 12/01/2022] [Accepted: 12/05/2022] [Indexed: 12/14/2022] Open
Abstract
For over 20 years, bovine beta-casein has been a subject of increasing scientific interest because its genetic A1 variant during gastrointestinal digestion releases opioid-like peptide β-casomorphin-7 (β-CM-7). Since β-CM-7 is involved in the dysregulation of many physiological processes, there is a growing discussion of whether the consumption of the β-casein A1 variant has an influence on human health. In the last decade, the number of papers dealing with this problem has substantially increased. The newest clinical studies on humans showed a negative effect of variant A1 on serum glutathione level, digestive well-being, cognitive performance score in children, and mood score in women. Scientific reports in this field can affect the policies of dairy cattle breeders and the milk industry, leading to the elimination of allele A1 in dairy cattle populations and promoting milk products based on milk from cows with the A2A2 genotype. More scientific proof, especially in well-designed clinical studies, is necessary to determine whether a little difference in the β-casein amino acid sequence negatively affects the health of milk consumers.
Collapse
Affiliation(s)
- Anna Cieślińska
- Department of Biochemistry, Faculty of Biology and Biotechnology, University of Warmia and Mazury, 10-719 Olsztyn, Poland
| | - Ewa Fiedorowicz
- Department of Biochemistry, Faculty of Biology and Biotechnology, University of Warmia and Mazury, 10-719 Olsztyn, Poland
| | - Dominika Rozmus
- Department of Biochemistry, Faculty of Biology and Biotechnology, University of Warmia and Mazury, 10-719 Olsztyn, Poland
| | - Edyta Sienkiewicz-Szłapka
- Department of Biochemistry, Faculty of Biology and Biotechnology, University of Warmia and Mazury, 10-719 Olsztyn, Poland
| | - Beata Jarmołowska
- Department of Biochemistry, Faculty of Biology and Biotechnology, University of Warmia and Mazury, 10-719 Olsztyn, Poland
| | - Stanisław Kamiński
- Department of Animal Genetics, University of Warmia and Mazury, 10-719 Olsztyn, Poland
| |
Collapse
|
3
|
F Nahhas A, F Nahhas A, J Webster T. Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics. Nanomedicine (Lond) 2021; 16:1237-1254. [PMID: 33988037 PMCID: PMC8120868 DOI: 10.2217/nnm-2020-0447] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Accepted: 03/29/2021] [Indexed: 01/13/2023] Open
Abstract
Viral infections are historically very difficult to treat. Although imperfect and time-consuming to develop, we do have some conventional vaccine and therapeutic approaches to stop viral spreading. Most importantly, all of this takes significant time while viruses continue to wreak havoc on our healthcare system. Furthermore, viral infections are accompanied by a weakened immune system which is often overlooked in antiviral drug strategies and requires additional drug development. In this review, for the first time, we touch on some promising alternative approaches to treat viral infections, specifically those focused on the use of platform nanomaterials with antiviral peptides. In doing so, this review presents a timely discussion of how we need to change our old way of treating viruses into one that can quickly meet the demands of COVID-19, as well as future pandemic-causing viruses, which will come.
Collapse
Affiliation(s)
- Alaa F Nahhas
- Biochemistry Department, College of Science, King Abdulaziz University, Jeddah 21589, KSA
| | - Alrayan F Nahhas
- Biochemistry Department, College of Science, King Abdulaziz University, Jeddah 21589, KSA
| | - Thomas J Webster
- Department of Chemical Engineering, College of Engineering, Northeastern University, Boston, MA 02115, USA
| |
Collapse
|
4
|
Summer A, Di Frangia F, Ajmone Marsan P, De Noni I, Malacarne M. Occurrence, biological properties and potential effects on human health of β-casomorphin 7: Current knowledge and concerns. Crit Rev Food Sci Nutr 2020; 60:3705-3723. [PMID: 32033519 DOI: 10.1080/10408398.2019.1707157] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The genetic variant A1 of bovine β-casein (β-Cn) presents a His residue at a position 67 of the mature protein. This feature makes the Ile66-His67 bond more vulnerable to enzymatic cleavage, determining the release of the peptide β-Cn f(60-66), named β-casomorphin 7 (BCM7). BCM7 is an opioid-agonist for μ receptors, and it has been hypothesized to be involved in the development of different non-transmissible diseases in humans. In the last decade, studies have provided additional results on the potential health impact of β-Cn A1 and BCM7. These studies, here reviewed, highlighted a relation between the consumption of β-Cn A1 (and its derivative BCM7) and the increase of inflammatory response as well as discomfort at the gastrointestinal level. Conversely, the role of BCM7 and the effects of ingestion of β-Cn A1 on the onset or worsening of other non-transmissible diseases as caused or favored by still need proof of evidence. Overall, the reviewed literature demonstrates that the "β-Cn A1/BCM7 issue" remains an intriguing but not exhaustively explained topic in human nutrition. On this basis, policies in favor of breeding for β-Cn variants not releasing BCM7 and consumption of "A1-like" milk appear not yet sound for a healthier and safer nutrition.
Collapse
Affiliation(s)
- Andrea Summer
- Department of Veterinary Sciences, Università di Parma, Parma, Italy
| | | | - Paolo Ajmone Marsan
- Department of Animal Science, Food and Nutrition (DIANA) and Nutrigenomics and Proteomics Research Center (PRONUTRIGEN), Università Cattolica del Sacro Cuore, Piacenza, Italy
| | - Ivano De Noni
- Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, Milan, Italy
| | - Massimo Malacarne
- Department of Veterinary Sciences, Università di Parma, Parma, Italy
| |
Collapse
|
5
|
Davis TP, Abbruscato TJ, Egleton RD. Peptides at the blood brain barrier: Knowing me knowing you. Peptides 2015; 72:50-6. [PMID: 25937599 PMCID: PMC4627938 DOI: 10.1016/j.peptides.2015.04.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 04/20/2015] [Accepted: 04/21/2015] [Indexed: 12/15/2022]
Abstract
When the Davis Lab was first asked to contribute to this special edition of Peptides to celebrate the career and influence of Abba Kastin on peptide research, it felt like a daunting task. It is difficult to really understand and appreciate the influence that Abba has had, not only on a generation of peptide researchers, but also on the field of blood brain barrier (BBB) research, unless you lived it as we did. When we look back at our careers and those of our former students, one can truly see that several of Abba's papers played an influential role in the development of our personal research programs.
Collapse
Affiliation(s)
- Thomas P Davis
- The Davis Lab, Department of Medical Pharmacology, University of Arizona, Tucson, AZ 85724-5050.
| | - Thomas J Abbruscato
- Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, TX 79106
| | - Richard D Egleton
- Joan C. Edwards School of Medicine at Marshall University, Huntington, WV 25755
| |
Collapse
|
6
|
|
7
|
Höistad M, Samskog J, Jacobsen KX, Olsson A, Hansson HA, Brodin E, Fuxe K. Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. Brain Res 2005; 1041:167-80. [PMID: 15829226 DOI: 10.1016/j.brainres.2005.02.014] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2004] [Revised: 01/29/2005] [Accepted: 02/01/2005] [Indexed: 11/16/2022]
Abstract
We have investigated to what extent microinjected beta-endorphin could migrate from the rat brain parenchyma into the CSF compartment. Exogenous rat beta-endorphin (0.1 nmol) was microinjected into the left striatum 1 mm from the lateral ventricle in anesthetized male rats. CSF samples were collected at different time points up to 2 h post-injection from a catheter affixed to the atlanto-occipital membrane of the cisterna magna. Radioimmunoassay and mass spectrometry were performed on the CSF samples, and brain sections were immunostained for beta-endorphin and mu-opioid receptors. The beta-endorphin injected rats showed a marked increase in beta-endorphin immunoreactive (IR) material in the CSF, with a peak at 30-45 min post-injection, and this beta-endorphin-IR material existed mainly as the intact beta-endorphin peptide. The immunohistochemistry results revealed the appearance of distinct beta-endorphin-IR cell bodies in the globus pallidus and the bed nucleus of stria terminalis supracapsular part, regions distant from the injection site, at 2 h post-injection of exogenous beta-endorphin. The beta-endorphin-IR in several of the globus pallidus cell bodies colocalized with the mu-opioid receptor-IR at the cell surface. These findings show that upon delivery of synthetic beta-endorphin, there is a significant intracerebral spread of the injected peptide, reaching regions far from the site of injection via diffusion in the extracellular space and flow in the cerebrospinal fluid. This may be of relevance when interpreting studies based on intracerebral injections of peptides, and advances our knowledge regarding the migration of compounds within the brain.
Collapse
Affiliation(s)
- Malin Höistad
- Department of Neuroscience, Karolinska Institutet, Retziusv. 8, 17177 Stockholm, Sweden.
| | | | | | | | | | | | | |
Collapse
|
8
|
Nonaka N, Shioda S, Niehoff ML, Banks WA. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther 2003; 306:948-53. [PMID: 12750431 DOI: 10.1124/jpet.103.051821] [Citation(s) in RCA: 122] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Peptide YY3-36 (PYY) has emerged as an important signal in the gut-brain axis, with peripherally administered PYY affecting feeding and brain function. For these effects to be direct, PYY would have to cross the blood-brain barrier (BBB). Here, we determined the permeability of the BBB to PYY radioactively labeled with 131I (I-PYY). Multiple-time regression analysis showed the unidirectional influx rate (Ki) from blood-to-brain for I-PYY to be 0.49 +/- 0.19 microl/g-min, a rate similar to that previously measured for leptin. Influx was not inhibited by 1 microg/mouse of unlabeled PYY, suggesting PYY crosses the BBB by transmembrane diffusion. About 0.176% of the i.v.-injected dose of I-PYY was taken up by brain, an amount similar to that for other peptides important in gut-brain communication. Capillary depletion showed that 69% of I-PYY crossed the BBB to enter the parenchymal space of the brain, and high-performance liquid chromatography demonstrated that the radioactivity in this space represented intact I-PYY. After intracerebroventricular injection, I-PYY crossed from brain to blood by the mechanism of bulk flow. We conclude that PYY crosses in both the blood-to-brain and brain-to-blood directions by nonsaturable mechanisms. Passage across the BBB provides a mechanism by which blood-borne PYY can affect appetite and brain function.
Collapse
Affiliation(s)
- Naoko Nonaka
- Oral Anatomy, School of Dentistry, Showa University, Tokyo, Japan
| | | | | | | |
Collapse
|
9
|
Chiocchio SR, Gallardo MG, Louzan P, Gutnisky V, Tramezzani JH. Melanin-concentrating hormone stimulates the release of luteinizing hormone-releasing hormone and gonadotropins in the female rat acting at both median eminence and pituitary levels. Biol Reprod 2001; 64:1466-72. [PMID: 11319153 DOI: 10.1095/biolreprod64.5.1466] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
The purpose of this study was to investigate whether melanin-concentrating hormone (MCH) acts directly on the median eminence and on the anterior pituitary of female rats regulating LHRH and gonadotropin release. In addition, immunohistochemistry was used to examine the density and distribution of MCH-immunoreactive fibers in the median eminence of proestrous rats. MCH-immunoreactive fibers were found in both the internal and external layers of the median eminence and in close association with hypophysial portal vessels. In the first series of in vitro experiments, median eminences and anterior pituitaries were incubated in Krebs-Ringer bicarbonate buffer containing two MCH concentrations (10(-10) and 10(-8) M). The lowest MCH concentration (10(-10) M) increased (P < 0.01) LHRH release only from proestrous median eminences. Anterior pituitaries incubated with both MCH concentrations also showed that 10(-10) M MCH increased gonadotropin release only from proestrous pituitaries. In the second series of experiments, median eminences and pituitaries from proestrous rats were incubated with graded concentrations of MCH. MCH (10(-10) and 10(-9) M) increased (P < 0.01) LHRH release from the median eminence, and only 10(-10) M MCH increased (P < 0.01) LH and FSH release from the anterior pituitary. The effect of MCH on the stimulation of both gonadotropins from proestrous pituitaries was similar to the effect produced by LHRH. Simultaneous incubation of pituitaries with MCH and LHRH did not modify LH but increased the FSH release induced by LHRH. The present results suggest that MCH could be involved in the regulation of preovulatory gonadotropin secretion.
Collapse
Affiliation(s)
- S R Chiocchio
- Instituto de Neurobiología, Buenos Aires 1414, Argentina.
| | | | | | | | | |
Collapse
|
10
|
Díaz-Cabiale Z, Narváez JA, García-Coronel M, Fuxe K. Galanin/alpha2-adrenoceptor interactions in telencephalic and diencephalic regions of the rat. Neuroreport 2001; 12:151-5. [PMID: 11201077 DOI: 10.1097/00001756-200101220-00038] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The aim of this study was to evaluate whether galanin could affect central alpha2-adrenoceptors in telencephalic and diencephalic regions in the rat using quantitative receptor autoradiography with the alpha2 agonist radioligand [3H]p-aminoclonidine. Galanin 1 nM significantly and substantially increased the Kd value of the [3H]p-aminoclonidine binding sites in the medial hypothalamus and amygdala by 86% (p < 0.01) and 73% (p < 0.05) respectively. The Bmax value was only significantly increased with 3 nM galanin in the amygdala and the medial hypothalamus (both p < 0.05). The antagonist M35 counteracted the increase of the Kd values of the alpha2-adrenoceptor agonist binding sites produced by galanin 1 nM in the amygdala and the medial hypothalamus (both p < 0.001). These findings suggest the existence of an antagonistic galanin/alpha2 adrenoceptor interaction in the medial hypothalamus and amygdala that may be of relevance for alpha2-adrenoceptor-regulated neuroendocrine functions and food intake.
Collapse
Affiliation(s)
- Z Díaz-Cabiale
- Department of Neuroscience (BZ-lab), Karolinska Institute, Stockholm, Sweden
| | | | | | | |
Collapse
|
11
|
Díaz-Cabiale Z, Narváez JA, Garrido R, Petersson M, Uvnäs-Moberg K, Fuxe K. Antagonistic oxytocin/alpha2-adrenoreceptor interactions in the nucleus tractus solitarii: relevance for central cardiovascular control. J Neuroendocrinol 2000; 12:1167-73. [PMID: 11106973 DOI: 10.1046/j.1365-2826.2000.00571.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The modulation of the central cardiovascular effects of alpha2-adrenoceptor activation by oxytocin in the nucleus tractus solitarii has been evaluated by cardiovascular analysis and by quantitative receptor autoradiography. Microinjections in the nucleus tractus solitarii of a threshold dose of oxytocin effectively and significantly counteracted the vasodepressor and bradycardic actions of an ED50 dose of the alpha2-adrenoceptor agonist clonidine. The coinjection of a threshold dose of oxytocin with a threshold dose of clonidine did not produce any changes in the mean arterial pressure but a tachycardic response was observed. Receptor autoradiographical experiments showed that oxytocin (3 nM) significantly increased the Kd and Bmax values of [3H]p-aminoclonidine binding sites in the nucleus tractus solitarii compatible with a possible antagonistic interaction with the alpha2-adrenoceptors, and this effect was blocked by the presence of the specific oxytocin receptor antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin. These findings suggest the existence of an antagonistic oxytocin/alpha2-adrenoceptor interaction in nucleus tractus solitarii that may be of relevance for the demonstrated modulation of alpha2-adrenoceptor induced cardiovascular responses by oxytocin.
Collapse
Affiliation(s)
- Z Díaz-Cabiale
- Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
| | | | | | | | | | | |
Collapse
|
12
|
Hol EM, Gispen WH, Bär PR. ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Peptides 1995; 16:979-93. [PMID: 7479345 DOI: 10.1016/0196-9781(95)00017-e] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
ACTH-related peptides are promising neurotrophic and neuroprotective agents, as demonstrated in many in vivo and in vitro studies. They accelerate nerve repair after injury, improving both sensor and motor function. Furthermore, ACTH-related peptides have neuroprotective properties against cisplatin- and taxol-induced neurotoxicity, they improve neuronal function in animals with neuropathy due to experimental diabetes, and they prevent degeneration of myelinated axons in rats suffering from experimental allergic neuritis, a model of peripheral demyelinating neuropathy. Studies in neuronal cultures have corroborated these clinical observations and serve to investigate the mechanism of action of the ACTH-related peptide effects. This paper reviews both in vitro and in vivo effects and emphasizes the mechanism of action. Recent data on melanotrophic receptors and signal transduction systems will be discussed in this context.
Collapse
Affiliation(s)
- E M Hol
- Department of Neurology, Rudolf Magnus Institute for Neurosciences, Utrecht University, The Netherlands
| | | | | |
Collapse
|
13
|
Hol EM, Sodaar P, Bär PR. Dorsal root ganglia as an in vitro model for melanocortin-induced neuritogenesis. Pharmacological and mechanistic aspects. Ann N Y Acad Sci 1994; 739:74-86. [PMID: 7832498 DOI: 10.1111/j.1749-6632.1994.tb19808.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- E M Hol
- Department of Neurology, Rudolf Magnus Institute, Utrecht University, The Netherlands
| | | | | |
Collapse
|
14
|
Vaccarino FJ, Kennedy SH, Ralevski E, Black R. The effects of growth hormone-releasing factor on food consumption in anorexia nervosa patients and normals. Biol Psychiatry 1994; 35:446-51. [PMID: 8018795 DOI: 10.1016/0006-3223(94)90042-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Current evidence from animal studies indicate that growth hormone-releasing factor (GRF) has direct effects on mechanisms controlling eating behavior. There is also evidence that eating disorder patients have abnormalities in their GRF-growth hormone (GH) axis. The present study investigated the possibility that GRF abnormalities contribute to the expression of abnormal eating patterns in anorexia nervosa (AN) patients, and that GRF has therapeutic potential in this regard. To this end, patients diagnosed with anorexia nervosa or combined anorexia nervosa/bulimia nervosa (AN/BN), as well as normal female subjects, were tested for their eating and GH responses following intravenous infusion of GRF (1 micrograms/kg) or placebo. Results indicated that GRF stimulates food consumption in AN patients and attenuates the elevated food consumption in AN/BN patients. These results are consistent with the notion that GRF abnormalities contribute to abnormal eating behavior, and provide preliminary evidence for the therapeutic potential of GRF in such conditions. The extent to which the present effects of GRF are dependent on nutritional status, GH actions, or direct central actions of GRF, are discussed.
Collapse
Affiliation(s)
- F J Vaccarino
- Department of Psychiatry, University of Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
15
|
Abstract
Because of the enormous growth over the last three decades of research on the role of peptides in the brain, the need became apparent to determine the status of these compounds in terms of their current research interest. Since 1965, over a quarter of a million research papers have been published on peptides that have since been classified as neuroactive. The present study was undertaken to analyze systematically the yearly trends of research emphasis in neuroactive peptides as reflected by their individual frequency of publication by year, beginning in 1966. A computer analysis of the publication characteristics was carried out using the Medline data base in which the citation search was limited to the topic brain crossed with the topic mammal. One criterion for the inclusion of a given peptide in the analysis was a frequency of 25 or more citations following its discovery, as related to the mammalian brain. The 42 peptides that met this criterion were: adrenocorticotropic hormone, angiotensin II, atrial natriuretic factor, bombesin, bradykinin, calcitonin, calcitonin gene-related peptide, carnosine, beta-casomorphin, cholecystokinin, corticotropin-releasing factor, delta sleep-inducing peptide, dynorphin, beta-endorphin, Leu-enkephalin, Met-enkephalin, galanin, gastrin, glucagon, growth hormone, growth hormone-releasing factor, insulin, kyotorphin, beta-lipotropin, luteinizing hormone-releasing factor, melanocyte-stimulating hormone release inhibitory factor-1, alpha-melanocyte-stimulating hormone, motilin, neurokinin A, neurokinin B, neuropeptide Y, neurotensin, oxytocin, pituitary adenylate cyclase activating polypeptide, peptide HI, prolactin, secretin, somatostatin, substance P, thyroid-releasing hormone, vasopressin, and vasoactive intestinal peptide. An overall analysis of the 298,105 papers published on these 42 peptides since 1965 revealed that the research activity of 24,742, or 8.30%, of the studies, focused on their neuroactive properties. Taken as a whole, the research on neuroactive peptides reached a peak in 1986, as reflected by the total of 1793 papers published during that year. Although the level of publication has fluctuated between 1548 and 1774 research papers over the last 6 years, it is now clear that the trend in research on neuroactive peptides has reached an asymptote today that shows no sign of deviation. A temporal analysis year by year of individual publication profiles revealed three distinct trends: 1) peptides showed a slow development in research interest and did not exceed more than 15-30 publications per year; 2) peptides exhibited a steady increase in research activity over the years that continues today; and 3) peptides displayed an initial, often intense, research emphasis that inexplicably declined, in some cases precipitously, in the mid 1980s.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- R D Myers
- Department of Pharmacology, School of Medicine, East Carolina University, Greenville, NC 27858
| |
Collapse
|
16
|
Meyer ME. The effects of methionine-enkephalin and its related metabolites upon the duration of the dorsal immobility response in rats. Pharmacol Biochem Behav 1993; 46:841-5. [PMID: 8309964 DOI: 10.1016/0091-3057(93)90210-k] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The effects of SC injections of methionine-enkephalin (Met1-5-Enk) and its N-terminal and C-terminal fragments upon the duration of the dorsal immobility response (DIR) over a 60-min time course were investigated. Experiment 1 analyzed the effects of various dosages (0.00-100.0 micrograms/kg) on DIR resulting in a potentiation of the duration in a dose-time course function. The effects of various fragments of Met1-5-Enk (10.0 micrograms/kg) from the N-terminal in Experiment 2 and from the C-terminal in Experiment 3 on the DIR resulted in the potentiation of the duration with the Met2-5-Enk and Met1-3-Enk fragments. All other fragments were not significant. The results were discussed in reference to the processing and metabolism of Met1-5-Enk.
Collapse
Affiliation(s)
- M E Meyer
- Department of Psychology, University of Florida, Gainesville 32611
| |
Collapse
|
17
|
Affiliation(s)
- P R Bär
- Department of Neurology, Rudolf Magnus Institute, Utrecht University, The Netherlands
| | | | | |
Collapse
|
18
|
Abstract
Acute recombinant human growth hormone (r-hGH) administration (1-250 micrograms/kg; IP) decreased locomotor activity (LA) in a dose-dependent manner, F(5, 43) = 3.55, p < 0.009, with maximum effect at a dose of 10 micrograms/kg [control = 1655 +/- 659 inputs/outputs (I/O); r-hGH = 909 +/- 436 I/O; p < 0.05]. The daily treatment with r-hGH (10 micrograms/kg/day; 5 days; IP) reduced LA counts during the first trial, with no apparent changes in motor behavior after habituation. In contrast, growth hormone-releasing factor (GRF; 10 micrograms/rat/day; 5 days; IP) enhanced LA (control = 1045 +/- 566 I/O; GRF = 2284 +/- 894 I/O; p < 0.01) during the 5-day treatment period, inhibiting habituation. Moreover, the individual differences in LA persisted during the treatment period in response to GRF or r-hGH, but not in control rats. These results seem to indicate that the effects of GRF on LA are not mediated by the release of peripheral GH, and suggest that GRF might influence psychomotor behavior by a central mechanism.
Collapse
Affiliation(s)
- X A Alvarez
- Department of Human Physiology, Complutense University Medical School, Madrid, Spain
| | | |
Collapse
|
19
|
Rubin Y, Duvdevani P, Ishay JS. Cardiovascular haemodynamics of oriental hornet venom sac extract. PHARMACOLOGY & TOXICOLOGY 1993; 72:268-72. [PMID: 8372045 DOI: 10.1111/j.1600-0773.1993.tb01648.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The effects of hornet venom sac extract on the functioning of the cardiovascular system was assessed in dogs by concomitant examination of the following parameters: Systemic blood pressure, blood pressure and the dp/dt derivative of the left ventricle of the heart, heart rate, direct measurement of the left ventricular wall thickness, cardiac output, and body temperature. The effect of adult hornet venom sac extract on the canine cardiovascular system was rapid and led to a sharp drop in the systemic blood pressure, a similar drop in the pressure and dp/dt derivative in the left ventricle, to bradycardia, immediate thickening of the left ventricular wall and to an immediate rise in the cardiac output. As for the canine temperature, this dropped immediately following the administration of venom sac extract and remained at the new low level for at least 30 min. The smaller molecular weight components (less than 10 kilodalton) in venom sac extract have been found to be responsible for the immediate effects of venom sac extract on the cardiovascular system. On the other hand the high-molecular weight components exert more delayed effects which lead to a cumulative disturbance of cardiac function.
Collapse
Affiliation(s)
- Y Rubin
- Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
| | | | | |
Collapse
|
20
|
Yee DK, Pastuszko A, Wilson DF. The effect of neurocatin on protein phosphorylation in striatal synaptosomes from rat brain. J Neurochem 1993; 60:1220-7. [PMID: 8095970 DOI: 10.1111/j.1471-4159.1993.tb03280.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Neurocatin, a neuroregulatory factor isolated from mammalian brain, is a powerful affector of protein phosphorylation in rat striatal synaptosomes. Two major synaptosomal phosphoproteins of approximately 80 and approximately 60 kDa, possibly synapsin I and tyrosine hydroxylase, were especially sensitive to neurocatin. Immunoprecipitation experiments confirmed that the 60-kDa protein is the enzyme tyrosine hydroxylase. At low concentrations of neurocatin (to approximately 7.5 ng/100 microliters of suspension), incorporation of 32P orthophosphate into these proteins increased with increasing neurocatin concentration. At 7.5 ng of neurocatin, incorporation of the label into the two proteins increased by 22 and 26%, respectively. Concentrations of neurocatin > 7.5 ng/100 microliters caused progressive decrease in incorporation of 32P into many synaptosomal proteins; by a concentration of neurocatin of approximately 45 ng/100 microliters, the level of 32P incorporation into many proteins was < or = 70% of control. The effects of neurocatin on synaptosomal protein phosphorylation were also dependent on the time of incubation. At a constant concentration of approximately 7.5 ng/100 microliters of neurocatin, increased incorporation of 32P into many proteins was measurable within 0.5 min and was maximal by 1 min. Incubation times > 2.0 min, showed progressive decrease in 32P incorporation. Removing extrasynaptosomal Ca2+ with EGTA attenuated the increased 32P incorporation induced by low neurocatin concentrations, suggesting that calcium plays a role in neurocatin-induced phosphorylation of rat striatal synaptosomal proteins. The reduced incorporation of label induced by high neurocatin concentrations, however, was not calcium dependent. The effects of neurocatin on the level of 32P incorporation into proteins were observed only in intact synaptosomes, consistent with this compound acting through receptors on the plasma membrane.
Collapse
Affiliation(s)
- D K Yee
- Department of Biochemistry and Biophysics, Medical School, University of Pennsylvania, Philadelphia 19104
| | | | | |
Collapse
|
21
|
Meyer ME. Intrastriatal injections of dynorphin A fragments potentiate the dorsal immobility response in rats. Pharmacol Biochem Behav 1993; 44:329-32. [PMID: 8095341 DOI: 10.1016/0091-3057(93)90469-a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The effects of bilateral intrastriatal injections (2.0 micrograms/side) of Dynorphin A 1-17 (Dyn A 1-17) and Dynorphin A 1-8 (Dyn A 1-8) and their related nonopioid fragments upon the dorsal immobility response (DIR) over a 1-h time course were investigated. Dyn A 1-17 and Dyn A 2-17 potentiated the duration of the DIR 5 min postinjection, whereas Dyn A 1-8 and Dyn A 2-8 potentiated the DIR duration at each time point over the hour with their greatest effect at 15 min. An SC injection of 4 mg/kg naloxone 15 min prior to central injections blocked the potentiation of the DIR effects of Dyn A.
Collapse
Affiliation(s)
- M E Meyer
- Department of Psychology, University of Florida, Gainesville 32611
| |
Collapse
|
22
|
Nezhat C, Nezhat F. Reply. Am J Obstet Gynecol 1993. [DOI: 10.1016/0002-9378(93)90528-q] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Meyer ME, van Hartesveldt C, Cottrell GA. Potentiation of the dorsal immobility response following intrastriatal injections of enkephalins. Pharmacol Biochem Behav 1992; 42:613-7. [PMID: 1513843 DOI: 10.1016/0091-3057(92)90006-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The effects of bilateral intrastriatal injections (1.0 microgram/side) of leucine5- and methionine5-enkephalins and their related nonopiate fragments upon three measures of immobility over a time course were investigated. Both leucine5-enkephalin and des-Tyr1-leucine-enkephalin potentiated the duration of the dorsal immobility response (DIR) 15 min postinjection and over a 1-h time course. On the other hand, methionine5-enkephalin and des-Tyr1-methionine-enkephalin potentiated the duration of the DIR at 5 and 15 min. These enkephalins and their fragments had no effect upon vertical cling and bar catalepsy. In a second study, an SC injection of 4 mg/kg naloxone 15 min prior to the central injections blocked the potentiation of the DIR effects of the enkephalins.
Collapse
Affiliation(s)
- M E Meyer
- Department of Psychology, University of Florida, Gainesville 32611
| | | | | |
Collapse
|
24
|
Janak PH, Schulteis G, Martinez JL. Uptake and metabolism of [3H]-Leu-enkephalin following either its intraperitoneal or subcutaneous administration to mice. Peptides 1992; 13:551-5. [PMID: 1523167 DOI: 10.1016/0196-9781(92)90088-k] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The uptake and metabolism of 30 micrograms/kg [3H]-Leu-enkephalin ([3H]-LE) following either intraperitoneal (IP) or subcutaneous (SC) administration to Swiss Webster mice was examined. Uptake of [3H] was rapid, with peak levels of radioactivity in plasma observed at 5 or 10 min following IP or SC peptide injection, respectively. The majority (80-99% +/- 0.8) of plasma radioactivity at all postinjection plasma collection time points was in the form of tyrosine-containing enkephalin metabolites, indicating a substantial and rapid in vivo hydrolysis rate for exogenously administered LE. Leu-enkephalin is metabolized in vivo faster than previously reported in vitro in mouse plasma. However, despite this extensive hydrolysis, levels of intact LE remaining in plasma following its systemic administration are within or above endogenous LE plasma levels.
Collapse
Affiliation(s)
- P H Janak
- Department of Psychology, University of California, Berkeley 94720
| | | | | |
Collapse
|
25
|
Abstract
The polypeptide mastoparan, isolated from the venom of the Oriental Hornet, Vespa orientalis, induces hypothermia in white mice 15 minutes after its intraperitoneal injection. The hypothermic effect is induced by mastoparan obtained from different hornet and wasp venoms. The normal murine core temperature is lowered by mastoparan from 38 degrees C to as far as 33 degrees C. This lowering lasts for one hour and is reversible.
Collapse
Affiliation(s)
- P Duvdevani
- Department of Physiology and Pharmacology, Sackler Medical School, Tel Aviv University, Ramat Aviv, Israel
| | | | | |
Collapse
|